C96.9
Conditions
Interventions
Group 1: Isolation of peripheral blood mononuclear cells from healthy donors in order to cultivate ?d T cells.
Group 2: Isolation of cancer cell from the peripheral blood or bone marrow blood from pat
Sponsors
Klinikum Nürnberg - Hämatologie/Onkologie
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Healthy donors: - Written consent Patients with haematological neoplasms: - Written consent - Medical indication for sampling
Exclusion criteria
Exclusion criteria: Healthy donors: - current illness - Previous donation for the same (sub-)project - Previous donation within the last 3 months Patients with haematological neoplasms: - unreasonable burden by additional sampling - assumed risk by additional sampling - delay of clinical diagnostics or therapy by study inclusion
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the study is to optimise the anti-cancer-effect of ?d T cells against malignant cells for a future clinical use. This includes the effector function of ?d T cells with a focus on the cytotoxicity against cancer cells as well as the in vitro expansion and stimulation of ?d T cells. After the stimulation, the effectiveness of ?d T cells is measured in in vitro assays against cancer cell lines and cancer cells, which are isolated from patient blood. We aim to increase the effectiveness of ?d T cells by adjusting the experimental conditions and the addition of therapeutically substances. | — |
Countries
Germany
Contacts
Public ContactStefan Knop
Klinikum Nürnberg - Hämatologie/Onkologie
Outcome results
None listed